March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
223 citations
,
September 2018 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
9 citations
,
July 2022 in “EMBO molecular medicine” Blocking certain immune signals can reduce skin damage from radiation therapy.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
9 citations
,
January 2024 in “International Journal of Dermatology” February 2026 in “Frontiers in Medicine” Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.
July 2025 in “Ultrasound in Medicine & Biology”
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
35 citations
,
August 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.
April 2016 in “Journal of Investigative Dermatology” Blocking certain proteins can significantly regrow hair in severe alopecia areata.
37 citations
,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
4 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” 11 citations
,
July 2014 in “Clinical Rheumatology” Cyclophosphamide often causes gastrointestinal issues, hair loss, and low blood cell counts in Chinese patients with autoimmune diseases.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
13 citations
,
October 2019 in “Journal of lasers in medical sciences” CO2 laser treatment for aging skin significantly changes immune system-related genes.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
January 2023 in “Dermatologic therapy” Diphenylcyclopropenone topical immunotherapy is effective for treating alopecia areata, with some side effects.
111 citations
,
February 2017 in “Antiviral research” Researchers found several compounds that could potentially treat Zika virus.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.